ScandiDos AB (publ) (SDOS.ST)
SEK 1.34
(1.13%)
SEK 1.34
(1.13%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.53 Million SEK | 56.82% |
| 2022 | -3.54 Million SEK | 43.18% |
| 2021 | -6.24 Million SEK | 30.03% |
| 2020 | -8.92 Million SEK | -72.37% |
| 2019 | -5.17 Million SEK | -132.64% |
| 2018 | 15.85 Million SEK | 345.12% |
| 2017 | -6.46 Million SEK | -24.79% |
| 2016 | -5.18 Million SEK | -586.3% |
| 2015 | 1.06 Million SEK | -62.56% |
| 2014 | 2.84 Million SEK | 118.02% |
| 2013 | -15.79 Million SEK | -353.64% |
| 2012 | 6.22 Million SEK | 591.34% |
| 2011 | 901 Thousand SEK | 2550.0% |
| 2010 | 34 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -19.1 Million SEK | -1148.14% |
| 2023 Q3 | -2.14 Million SEK | -29.78% |
| 2023 FY | -1.53 Million SEK | 56.82% |
| 2023 Q1 | 2.49 Million SEK | 170.33% |
| 2023 Q4 | -1.53 Million SEK | 28.59% |
| 2023 Q2 | -1.65 Million SEK | -166.24% |
| 2022 Q1 | -461 Thousand SEK | 92.61% |
| 2022 Q2 | -3.69 Million SEK | -700.65% |
| 2022 FY | -3.54 Million SEK | 43.18% |
| 2022 Q3 | -2.48 Million SEK | 32.67% |
| 2022 Q4 | -3.54 Million SEK | -42.7% |
| 2021 Q3 | -2.7 Million SEK | 64.01% |
| 2021 Q4 | -6.24 Million SEK | -130.38% |
| 2021 FY | -6.24 Million SEK | 30.03% |
| 2021 Q1 | -9.99 Million SEK | -12.09% |
| 2021 Q2 | -7.52 Million SEK | 24.71% |
| 2020 Q2 | -11.7 Million SEK | -1.73% |
| 2020 FY | -8.92 Million SEK | -72.37% |
| 2020 Q1 | -11.5 Million SEK | -122.28% |
| 2020 Q4 | -8.92 Million SEK | -13.94% |
| 2020 Q3 | -7.82 Million SEK | 33.1% |
| 2019 Q3 | -7.68 Million SEK | 16.34% |
| 2019 FY | -5.17 Million SEK | -132.64% |
| 2019 Q4 | -5.17 Million SEK | 32.66% |
| 2019 Q2 | -9.18 Million SEK | 34.7% |
| 2019 Q1 | -14.06 Million SEK | -188.71% |
| 2018 Q1 | -1.88 Million SEK | 70.92% |
| 2018 FY | 15.85 Million SEK | 345.12% |
| 2018 Q4 | 15.85 Million SEK | 79.74% |
| 2018 Q3 | 8.82 Million SEK | 50.09% |
| 2018 Q2 | 5.87 Million SEK | 412.49% |
| 2017 Q1 | -3.12 Million SEK | 39.7% |
| 2017 Q4 | -6.46 Million SEK | 20.25% |
| 2017 Q3 | -8.11 Million SEK | 28.31% |
| 2017 Q2 | -11.31 Million SEK | -262.0% |
| 2017 FY | -6.46 Million SEK | -24.79% |
| 2016 Q4 | -5.18 Million SEK | 45.73% |
| 2016 Q2 | -12.58 Million SEK | -222.89% |
| 2016 Q3 | -9.55 Million SEK | 24.12% |
| 2016 Q1 | 10.24 Million SEK | 860.88% |
| 2016 FY | -5.18 Million SEK | -586.3% |
| 2015 Q2 | -1.09 Million SEK | 87.6% |
| 2015 Q4 | 1.06 Million SEK | 142.18% |
| 2015 Q3 | -2.52 Million SEK | -130.57% |
| 2015 FY | 1.06 Million SEK | -62.56% |
| 2015 Q1 | -8.83 Million SEK | -410.36% |
| 2014 FY | 2.84 Million SEK | 118.02% |
| 2014 Q3 | 823 Thousand SEK | 128.18% |
| 2014 Q2 | -2.92 Million SEK | 68.82% |
| 2014 Q1 | -9.36 Million SEK | 40.71% |
| 2014 Q4 | 2.84 Million SEK | 245.93% |
| 2013 Q4 | -15.79 Million SEK | -335.28% |
| 2013 FY | -15.79 Million SEK | -353.64% |
| 2013 Q1 | 456 Thousand SEK | -92.68% |
| 2013 Q3 | 6.71 Million SEK | 0.0% |
| 2012 Q4 | 6.22 Million SEK | 0.0% |
| 2012 FY | 6.22 Million SEK | 591.34% |
| 2011 FY | 901 Thousand SEK | 2550.0% |
| 2010 FY | 34 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 95.644% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 100.125% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 100.125% |
| Arcoma AB | -1.12 Million SEK | -35.727% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 101.393% |
| BICO Group AB (publ) | 927.9 Million SEK | 100.165% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 101.189% |
| CellaVision AB (publ) | -56.94 Million SEK | 97.311% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 89.709% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | 81.893% |
| C-Rad AB (publ) | -127.6 Million SEK | 98.8% |
| Duearity AB (publ) | 10.23 Million SEK | 114.964% |
| Dignitana AB (publ) | 13.07 Million SEK | 111.708% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 97.095% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.028% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 95.632% |
| Iconovo AB (publ) | -10.75 Million SEK | 85.765% |
| Integrum AB (publ) | -10.47 Million SEK | 85.386% |
| Luxbright AB (publ) | -13.83 Million SEK | 88.933% |
| Mentice AB (publ) | -49.56 Million SEK | 96.911% |
| OssDsign AB (publ) | -162.78 Million SEK | 99.06% |
| Paxman AB (publ) | -11.41 Million SEK | 86.583% |
| Promimic AB (publ) | -50.32 Million SEK | 96.958% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 108.028% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 94.397% |
| Sectra AB (publ) | -772.85 Million SEK | 99.802% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 99.325% |
| Senzime AB (publ) | -139.54 Million SEK | 98.903% |
| SpectraCure AB (publ) | -50.23 Million SEK | 96.952% |
| Stille AB | -178.5 Million SEK | 99.142% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 100.125% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 99.287% |